Biolidics ties up with Japan's Sysmex to develop cancer diagnostic test
Add BT as a preferred source
Claudia Chong
CANCER diagnostics company Biolidics has inked a definitive agreement with Japan-based healthcare group Sysmex to jointly develop a liquid biopsy cancer diagnostic test. A liquid biopsy is a test done on a sample of blood to look for cancer cells.
Sysmex, which is listed on the Tokyo Stock Exchange, is one of the leading suppliers of haematology products. Haematology is the branch of medicine involving the study and treatment of diseases relating to the blood.
Sysmex supplies healthcare products and services to customers in more than 190 countries. Biolidics and Sysmex have been collaborating since 2016 for research and development.
Under the definitive agreement, both companies will combine their technologies to come up with a laboratory-developed test with an established workflow process.
The test, which will use just a small amount of blood sample, will be clinically validated by SAM Laboratory, an internationally accredited clinical laboratory owned by Clearbridge Health, Biolidics' controlling shareholder.
Upon successful validation, Biolidics will commercialise and market the jointly-developed cancer diagnostic test in Asia, outside of Japan.
Copyright SPH Media. All rights reserved.
TRENDING NOW
Ng Khee Siong, managing director of Borneo Motors parent Inchcape Singapore, resigns
Early payout from Philippines’ Maharlika Investment Fund raises eyebrows over its true nature
Malaysia data centre boom enters ‘reset mode’ as resource, funding realities bite: S&P
Kingsford Group inks deal to buy Tan Boon Liat Building at lower reserve price of S$950m
